FibroBiologics, Inc.

Healthcare · Biotechnology · United States

Last price 0.93 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 6.47M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company’s product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, includi...